JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis

BackgroundJanus kinase (JAK) inhibitors have been approved for the treatment of several immune-mediated diseases (IMIDs) including rheumatoid arthritis (RA) and psoriatic arthritis and are in clinical trials for numerous other IMIDs. However, detailed studies investigating the effects of different J...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Natalie Frede, Raquel Lorenzetti, Janika M Hüppe, Iga Janowska, Arianna Troilo, Marei-Theresa Schleyer, Ana C. Venhoff, Reinhard E. Voll, Jens Thiel, Nils Venhoff, Marta Rizzi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Subjects:	JAK inhibition B cells rheumatoid arthritis tofacitinib baricitinib ruxolitinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1087986/full